OBJECTIVES: We sought to determine hepatitis B virus (HBV) infection prevalence, associated exposures, and incidence among male inmates at a state correctional facility. METHODS: A cross-sectional serological survey was conducted in June 2000, and susceptible inmates were retested in June 2001. RESULTS: At baseline, 230 inmates (20.5%; 95% confidence interval [CI]=18.2%, 22.9%) exhibited evidence of HBV infection, including 11 acute and 11 chronic infections. Inmates with HBV infection were more likely than susceptible inmates to have injected drugs (38.8% vs 18.0%; adjusted prevalence odds ratio [OR]=3.0; 95% CI=1.9, 4.9), to have had more than 25 female sex partners (27.7% vs 17.5%; adjusted prevalence OR=2.0; 95% CI=1.4, 3.0), and to have been incarcerated for more than 14 years (38.4% vs 17.6%; adjusted prevalence OR=1.7; 95% CI=1.1, 2.6). One year later, 18 (3.6%) showed evidence of new HBV infection. Among 19 individuals with infections, molecular analysis identified 2 clusters involving 10 inmates, each with a unique HBV sequence. CONCLUSIONS: We documented ongoing HBV transmission at a state correctional facility. Similar transmission may occur at other US correctional facilities and could be prevented by vaccination of inmates.
OBJECTIVES: We sought to determine hepatitis B virus (HBV) infection prevalence, associated exposures, and incidence among male inmates at a state correctional facility. METHODS: A cross-sectional serological survey was conducted in June 2000, and susceptible inmates were retested in June 2001. RESULTS: At baseline, 230 inmates (20.5%; 95% confidence interval [CI]=18.2%, 22.9%) exhibited evidence of HBV infection, including 11 acute and 11 chronic infections. Inmates with HBV infection were more likely than susceptible inmates to have injected drugs (38.8% vs 18.0%; adjusted prevalence odds ratio [OR]=3.0; 95% CI=1.9, 4.9), to have had more than 25 female sex partners (27.7% vs 17.5%; adjusted prevalence OR=2.0; 95% CI=1.4, 3.0), and to have been incarcerated for more than 14 years (38.4% vs 17.6%; adjusted prevalence OR=1.7; 95% CI=1.1, 2.6). One year later, 18 (3.6%) showed evidence of new HBV infection. Among 19 individuals with infections, molecular analysis identified 2 clusters involving 10 inmates, each with a unique HBV sequence. CONCLUSIONS: We documented ongoing HBV transmission at a state correctional facility. Similar transmission may occur at other US correctional facilities and could be prevented by vaccination of inmates.
Authors: G M McQuillan; P J Coleman; D Kruszon-Moran; L A Moyer; S B Lambert; H S Margolis Journal: Am J Public Health Date: 1999-01 Impact factor: 9.308
Authors: Andrew P Wilper; Steffie Woolhandler; J Wesley Boyd; Karen E Lasser; Danny McCormick; David H Bor; David U Himmelstein Journal: Am J Public Health Date: 2009-01-15 Impact factor: 9.308
Authors: Amy Jo Harzke; Jacques Baillargeon; David P Paar; John Pulvino; Owen J Murray Journal: Am J Gastroenterol Date: 2009-04-21 Impact factor: 10.864
Authors: Karen A Hennessey; Andrea A Kim; Vivian Griffin; Nicoline T Collins; Cindy M Weinbaum; Keith Sabin Journal: J Urban Health Date: 2008-07-12 Impact factor: 3.671
Authors: Ethan Gough; Mirjam C Kempf; Laura Graham; Marvin Manzanero; Edward W Hook; Al Bartolucci; Eric Chamot Journal: BMC Public Health Date: 2010-12-21 Impact factor: 3.295
Authors: Richard P Sullivan; Rob Baird; Kevin Freeman; Hugh Heggie; Joshua S Davis; Catherine S Marshall; Jane Davies Journal: BMC Infect Dis Date: 2021-06-16 Impact factor: 3.090